Consolidated Balance Sheets - USD ($) $ in Millions		Dec. 31, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents		$ 416	$ 1,944
Short-term investments		22,316	29,125
Trade accounts receivable, less allowance for doubtful accounts: 2022—$449; 2021—$492		10,952	11,479
Inventories	[1]	8,981	9,059
Current tax assets		3,577	4,266
Other current assets		5,017	3,820
Total current assets		51,259	59,693
Equity-method investments		11,033	16,472
Long-term investments		4,036	5,054
Property, plant and equipment		16,274	14,882
Identifiable intangible assets	[2]	43,370	25,146
Goodwill	[3]	51,375	49,208
Noncurrent deferred tax assets and other noncurrent tax assets		6,693	3,341
Other noncurrent assets		13,163	7,679
Total assets		197,205	181,476
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2022—$2,560; 2021—$1,636		2,945	2,241
Trade accounts payable		6,809	5,578
Dividends payable		2,303	2,249
Income taxes payable		1,587	1,266
Accrued compensation and related items		3,407	3,332
Deferred revenues		2,520	3,067
Other current liabilities		22,568	24,939
Total current liabilities		42,138	42,671
Long-term debt		32,884	36,195
Pension and postretirement benefit obligations		2,250	3,724
Noncurrent deferred tax liabilities		1,023	349
Other taxes payable		9,812	11,331
Other noncurrent liabilities		13,180	9,743
Total liabilities		101,288	104,013
Commitments and Contingencies
Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2022 and December 31, 2021		0	0
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2022—9,519; 2021—9,471		476	473
Additional paid-in capital		91,802	90,591
Treasury stock, shares at cost: 2022—3,903; 2021—3,851		(113,969)	(111,361)
Retained earnings		125,656	103,394
Accumulated other comprehensive loss		(8,304)	(5,897)
Total Pfizer Inc. shareholders’ equity		95,661	77,201
Equity attributable to noncontrolling interests		256	262
Total equity		95,916	77,462
Total liabilities and equity		$ 197,205	$ 181,476

[1] The decrease from December 31, 2021 reflects lower levels of Comirnaty, partially offset by new products acquired through recent acquisitions and higher Paxlovid inventory levels.

[2] The increase is primarily due to acquisitions (see Note 2A), partially offset by amortization expense.

[3] As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see Note 1A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed this re-allocation during the fourth quarter 2022 and concluded that none of our goodwill was impaired. Our goodwill balance continues to be assigned within the Biopharma reportable segment.